CD45RA-depleted DLI for the Treatment of Refractory/Persistent Viral Infections After Haploidentical Transplantation

Sponsor
Ruijin Hospital
Study ID
NCT07662369
Phase
PHASE1/PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Haplo-identical HCT
  • Hematologic Malignancy

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

  • CD45RA depleted donor lymphocyte infusion (DLI) — BIOLOGICAL
    CD45RA depleted donor lymphocyte infusion (DLI) admission with escalated dose

Study Details

The goal of this clinical trial is to learn whether giving patients special donor immune cells (called "CD45RA Depleted DLI") can help treat viral infections that have not improved with standard antiviral drugs. These infections occur after a stem cell transplant. The study will also look at the safety of this treatment.

Key Dates

First listed
Jun 23, 2026
Start date
Jun 1, 2026
Status verified
May 2026
Primary completion
Jun 30, 2027
Completion
Jun 30, 2028

Study Design

Enrollment
30 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment Group
    CD45RA Depleted DLI

Primary Outcome Measure

Percentage of Participants Achieving Overall Response of Viral Infection Based on Quantitative PCR and Clinical Response Criteria [ Time Frame: 90 days after the first CD45RA-depleted donor lymphocyte infusion ]

Central Contacts

Related Studies